Pragya D Yadav, Viren Sardana, Gururaj Rao Deshpande, Pradnya V Shinde, Jeromie Wesley Vivian Thangaraj, Leyanna S George, Gajanan N Sapkal, Deepak Y Patil, Rima R Sahay, Anita M Shete, Madhavi Joshi, Manoj Murhekar, Sheela Godbole, Nivedita Gupta, Satyartha Prakash, Mamta Rathore, Rajat Ujjainiya, Ajay Pratap Singh, Aastha Mishra, Debasis Dash, Kumardeep Chaudhary, Shantanu Sengupta
BACKGROUND OBJECTIVES: The Omicron sub-lineages are known to have higher infectivity, immune escape and lower virulence. During December 2022 - January 2023 and March - April 2023, India witnessed increased SARS-CoV-2 infections, mostly due to newer Omicron sub-lineages. With this unprecedented rise in cases, we assessed the neutralization potential of individuals vaccinated with ChAdOx1 nCoV (Covishield) and BBV152 (Covaxin) against emerging Omicron sub-lineages. METHODS: Neutralizing antibody responses were measured in the sera collected from individuals six months post-two doses (n=88) of Covishield (n=44) or Covaxin (n=44) and post-three doses (n=102) of Covishield (n=46) or Covaxin (n=56) booster dose against prototype B...
March 21, 2024: Indian Journal of Medical Research